Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2066MR)

This product GTTS-WQ2066MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets Canlupfam PDCD1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Caninized
RefSeq NM_001314097.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 486213
UniProt ID A0A090BAM7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2066MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1189MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ3939MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ4448MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ12358MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ3113MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA APN311
GTTS-WQ14939MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SHR-1210
GTTS-WQ4820MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ4223MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW